The Oncology team at the SENS Research Foundation seeks to uncover the role of telomere lengthening in cancer development. In particular, the Alternative Lengthening of Telomeres (ALT) pathway accounts for about 10-15% of cancers, yet no ALT-specific anticancer therapeutics currently exist. In an effort to better characterize ALT activity, a high-content assay utilizing the ImageXpress® Micro System was established and validated to identify ALT-positive cells. This high content imaging workflow is not only ~20 times faster than the previous protocol, but also provides a standardized approach for assay development in this field.
ImageXpress Micro XLS
High-Content Analysis System